We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Pioglitazone (Actos)is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Pioglitazone (Actos) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2005–2016 with a typical study size of 5,238 participants.
Based on 6 studies · 1 meta-analysis · 4 RCTs · 33,658 total participants
Confidence
ModerateBy outcome
Pioglitazone (Actos) has an evidence score of 4/10 — moderate evidence based on 6 indexed studies, including 1 meta-analysis. An oral thiazolidinedione (Actos) diabetes drug that improves insulin sensitivity via PPAR-gamma. It drew geroscience interest after reducing recurrent stroke/MI in insulin-resistant non-diabetics (IRIS) and improving NASH liver histology — but weight gain, fluid retention / heart-failure risk, fracture risk, and a debated bladder-cancer signal keep enthusiasm in check. Prescription drug, not a supplement. Representative study: PMID 25173606.
The commonly studied dose of Pioglitazone (Actos) is Off-label metabolic use mirrors diabetes dosing (e.g. 15–45 mg once daily) under a clinician. A prescription drug; not an approved longevity regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Nicotinamide Riboside
Mostly mechanism / observationalA vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
Alirocumab (Praluent)
Last reviewed June 2026 · evidence from 6 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Pioglitazone (Actos) — thiazolidinedione PPAR-gamma agonist
An oral thiazolidinedione (Actos) diabetes drug that improves insulin sensitivity via PPAR-gamma. It drew geroscience interest after reducing recurrent stroke/MI in insulin-resistant non-diabetics (IRIS) and improving NASH liver histology — but weight gain, fluid retention / heart-failure risk, fracture risk, and a debated bladder-cancer signal keep enthusiasm in check. Prescription drug, not a supplement.
Pioglitazone has strong randomized human evidence for improving insulin sensitivity, reducing recurrent stroke/MI in insulin-resistant non-diabetics (IRIS), and improving NASH liver histology — but general longevity is unproven, and weight gain, fluid retention / heart-failure risk, fracture risk (esp. women), and a debated bladder-cancer signal keep the metabolic-longevity use at moderate.
Pioglitazone is an oral thiazolidinedione (TZD) — a PPAR-gamma agonist — approved for type 2 diabetes, where it improves insulin sensitivity by reprogramming adipocyte metabolism, lowering circulating free fatty acids, and redistributing fat away from liver and muscle.
That insulin-sensitizing, anti-inflammatory profile is why it appears on the metabolic-longevity map.
The strongest signal comes from the IRIS trial (NEJM 2016): in patients with insulin resistance but without diabetes who had a recent stroke or TIA, pioglitazone reduced recurrent stroke and myocardial infarction (and lowered progression to diabetes) versus placebo.
In type 2 diabetes, the large PROactive trial missed its primary composite endpoint but showed a significant reduction in a secondary composite of death, MI, and stroke.
Pioglitazone is also one of the few agents with randomized histologic evidence in non-alcoholic steatohepatitis (NASH/MASH): both Belfort (NEJM 2006) and Cusi's long-term trial (Ann Intern Med 2016) showed improved liver histology and NASH resolution.
The honest counterweight is real and well-documented: pioglitazone causes weight gain and fluid retention, raises heart-failure risk (it is contraindicated in symptomatic heart failure), increases bone-fracture risk — especially in women, where a meta-analysis put the odds ratio near 1.7 alongside reduced bone mineral density — and carries a long-debated, probably small bladder-cancer signal that some cohorts (e.g. a propensity-matched study) failed to confirm.
The score reflects genuinely strong human outcome and histologic data for insulin sensitivity, secondary cardiovascular prevention, and NASH, set against weight/edema/heart-failure/fracture harms and an unproven general-longevity claim.
Pioglitazone is a prescription drug; any off-label metabolic-longevity use is clinician-directed and not an approved or self-administered regimen.
Activates the nuclear receptor PPAR-gamma, reprogramming adipocyte gene expression and lipid storage to improve whole-body insulin sensitivity.
Lowers circulating free fatty acids and redistributes fat away from liver and muscle, reducing insulin resistance independent of insulin secretion.
Shifts fat toward subcutaneous depots and dampens metabolic inflammation — the proposed basis for its NASH and vascular benefits.
How Pioglitazone (Actos) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Off-label metabolic use mirrors diabetes dosing (e.g. 15–45 mg once daily) under a clinician. A prescription drug; not an approved longevity regimen.
Loading: No loading dose; usually started at 15–30 mg once daily and titrated to a 45 mg maximum.
Can be taken without food
| Form | Type |
|---|---|
| 💊Oral tablet (pioglitazone) | Recommended |
| 💊Other insulin sensitizers (e.g. metformin) where the TZD risk profile is unacceptable | Alternative |
Pioglitazone has the IRIS and NASH histology data; rosiglitazone (same class) carries a worse cardiovascular profile.
Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: Once daily, with or without food. Histologic and vascular benefits accrue over months; monitor weight and for edema/dyspnea.
Dose-response data unavailable. The current published research for Pioglitazone (Actos) does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Improves peripheral insulin sensitivity and lowers progression to diabetes in insulin-resistant patients.
In the IRIS trial, reduced recurrent stroke and myocardial infarction in insulin-resistant non-diabetic patients after stroke/TIA.
Randomized trials show improved liver histology and steatohepatitis resolution in NASH/MASH.
Causes weight gain and fluid retention and raises heart-failure risk — contraindicated in symptomatic heart failure.
Increases bone-fracture risk (especially in women) with lower BMD; a small, debated bladder-cancer signal is not confirmed in all cohorts.
Avoid — contraindicated in symptomatic heart failure; fluid retention can precipitate decompensation.
Caution — meta-analysis shows higher fracture risk in women; weigh against bone health.
Avoid pending the debated bladder-cancer signal.
Combined use increases fluid retention, weight gain, and heart-failure risk.
Markedly raises pioglitazone exposure; the dose should be reduced.
Additive hypoglycemia risk when combined.
Tip: Largely from fat gain and fluid retention; monitor weight and diet.
Tip: Can precipitate or worsen heart failure; report rapid weight gain, swelling, or shortness of breath.
Tip: Associated with lower BMD; weigh against fracture-risk factors, particularly in postmenopausal women.
Tip: Signal is small and not confirmed in all cohorts; avoid in active/prior bladder cancer and investigate unexplained hematuria.
The best time to take Pioglitazone (Actos) is in the morning. It can be taken on an empty stomach. Taken once daily without regard to meals; effects build over weeks.
Pioglitazone (Actos) should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are weight gain, fluid retention / edema, bone fracture (especially women). Use caution if any of these apply to you: Symptomatic heart failure (NYHA III–IV); Active or history of bladder cancer; Active liver disease / significant hepatic impairment.
A fully human monoclonal-antibody PCSK9 inhibitor (Praluent), injected under the skin every 2 weeks, that lowers LDL cholesterol by ~50–60%. In the ODYSSEY OUTCOMES trial of ~18,900 post-heart-attack patients it reduced major cardiovascular events and showed a possible all-cause mortality signal. Generally well tolerated; injection-site reactions and high cost/access are the main trade-offs. Prescription drug, not a supplement.